Evidence map›Paper›PMID 34671071›Full record

ArticleScientific reports2021

Reduced expression of OXPHOS and DNA damage genes is linked to protection from microvascular complications in long-term type 1 diabetes: the PROLONG study.

Türküler Özgümüş, Oksana Sulaieva, Leon Eyrich Jessen, Ruchi Jain, Henrik Falhammar, Thomas Nyström, Sergiu-Bogdan Catrina, Gun Jörneskog, Leif Groop, Mats Eliasson and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. The role and mechanisms of microvascular damage in the ischemic myocardium.Cellular and molecular life sciences : CMLS · 2023
    Review
  6. Review
  7. mActa biochimica et biophysica Sinica · 2023
    Review
  8. DNA Damage and Repair in Eye Diseases.International journal of molecular sciences · 2023
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Türküler ÖzgümüşDepartment of Clinical Science, Center for Diabetes Research, University of Bergen, 5032, Bergen, Norway.
Oksana SulaievaMedical Laboratory CSD, Vasylkivska Str. 45, Kyiv, Ukraine.
Leon Eyrich JessenSection for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
Ruchi JainDepartment of Clinical Sciences/Genomics, Diabetes and Endocrinology, Lund University Diabetes Centre, 205 02, Malmö, Sweden.
Henrik FalhammarDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Thomas NyströmUnit for Diabetes Research, Division of Internal Medicine, Department of Clinical Science and Education, Karolinska Institute, South Hospital, Stockholm, Sweden.
Sergiu-Bogdan CatrinaDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Gun JörneskogDivision of Internal Medicine, Department of Clinical Sciences, Karolinska Institute, Danderyd University Hospital, Stockholm, Sweden.
Leif GroopDepartment of Clinical Sciences/Genomics, Diabetes and Endocrinology, Lund University Diabetes Centre, 205 02, Malmö, Sweden.
Mats EliassonSunderby Research Unit, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Björn EliassonDepartment of Medicine, University of Gothenburg, Gothenburg, Sweden.
Kerstin BrismarDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Tomasz StokowyDepartment of Clinical Science, University of Bergen, 5021, Bergen, Norway.
Peter M NilssonDepartment of Clinical Sciences/Genomics, Diabetes and Endocrinology, Lund University Diabetes Centre, 205 02, Malmö, Sweden.
Valeriya LyssenkoDepartment of Clinical Science, Center for Diabetes Research, University of Bergen, 5032, Bergen, Norway. Valeriya.Lyssenko@uib.no.
Karolinska Institutet · SELund University · SEUniversity of Bergen · NOInstitute for Molecular Medicine Finland · FIKarolinska University Hospital · SETechnical University of Denmark · DKUmeå University · SEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes is a chronic autoimmune disease requiring insulin treatment for survival. Prolonged duration of type 1 diabetes is associated with increased risk of microvascular complications. Although chronic hyperglycemia and diabetes duration have been considered as the major risk factors for vascular complications, this is not universally seen among all patients. Persons with long-term type 1 diabetes who have remained largely free from vascular complications constitute an ideal group for investigation of natural defense mechanisms against prolonged exposure of diabetes. Transcriptomic signatures obtained from RNA sequencing of the peripheral blood cells were analyzed in non-progressors with more than 30 years of diabetes duration and compared to the patients who progressed to microvascular complications within a shorter duration of diabetes. Analyses revealed that non-progressors demonstrated a reduction in expression of the oxidative phosphorylation (OXPHOS) genes, which were positively correlated with the expression of DNA repair enzymes, namely genes involved in base excision repair (BER) machinery. Reduced expression of OXPHOS and BER genes was linked to decrease in expression of inflammation-related genes, higher glucose disposal rate and reduced measures of hepatic fatty liver. Results from the present study indicate that at transcriptomic level reduction in OXPHOS, DNA repair and inflammation-related genes is linked to better insulin sensitivity and protection against microvascular complications in persons with long-term type 1 diabetes.

Indexed as

AdultBlood GlucoseDiabetes Mellitus, Type 1DNA DamageFatty LiverFemaleHumansHyperglycemiaInsulin ResistanceLiverMaleMicrovesselsMiddle AgedOxidative PhosphorylationBlood Glucose

Identifiers

PMID34671071
PMCPMC8528906
OpenAlexW3206140985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.